Search
Close this search box.
Donation
Search
Close this search box.
Donation
News

Director of Nuclear Medicine​

Alexis Vrachimis

dct-VhrachimisAl

“Using molecular imaging and theranostics, our aim is to enable treatments tailored to the uniqueness of each patient.”

As Director of the Department of Nuclear Medicine, Associate Professor Dr. Alexis Vrachimis is in charge of its Diagnostic Unit of the Department, as well as of the Radioisotope Application Chamber. He was trained and worked in university clinics in Greece and Germany, and decided to leave a promising academic career and repatriate, so as to assist in the installation of a cyclotron and PET / CT in Cyprus – the first and still the only on the island. It was his vision to see this so very crucial service provided to our fellow citizens, and thus freeing them from the additional financial burden and inconvenience of having to travel abroad for it. Since June 2017, Dr. Vrachimis is a member of the medical team led by Professor Zamboglou, and has already seen tangible results from our dedication to providing high quality services in the relief of cancer patients in Cyprus, especially those services which were not available before.

Name: Alexis Vrachimis born on the 19th February 1984 in Nicosia, Cyprus
Citizenship: Cypriot
Marital Status: Married, 1 child
Languages: Greek (mother tongue), German (fluently), English (fluently)

  • 06/2021
    Professor for Nuclear Medicine of the Medical School of the European University of Cyprus

  • 10/2016
    Habilitation / Venia Legendi for Nuclear Medicine of the Medical School of the University of Münster (WWU), Germany

  • 2014-
    Specialist in Nuclear Medicine (Germany, Cyprus)

  • 2012 - 2014
    Lecturer at the Department for Radiology Assistants of the University Hospital Münster (UKM), Germany

  • 2009 - 2011
    Doctorate at the Medical School of the Medical School of the University of Münster (WWU), Germany

  • 2001 - 2007
    Medical Studies in the University of Ioannina, Greece

  • 01/2024-
    Secretary/Treasurer of the European Association of Nuclear Medicine

  • 06/2017-
    Director of the Department of Nuclear Medicine of the German Oncology Center in Limassol

  • 2022-2023
    National Delegate of Cyprus of the European Association of Nuclear Medicine

  • 2021-2023
    Vice Chair of the Thyroid Committee of the European Association of Nuclear Medicine

  • 2019-2023
    Member of the Thyroid Committee of the European Association of Nuclear Medicine

  • 2016-2019
    Member of the Thyroid Committee of the German Association of Nuclear Medicine

  • 2015 - 2017
    Clinical Researcher position at the Collaborative Research Center 656 MoBil "Cardiovascular Molecular Imaging" (sponsored by the German Research Foundation-DFG)

  • 2009 - 2014
    Medical specialty training at the Department of Nuclear Medicine of UKM, Germany

  • 2010 - 2012
    PostDoc researcher at the at the Collaborative Research Center 656 MoBil "Cardiovascular Molecular Imaging" (sponsored by the German Research Foundation-DFG)

  • 2009 - 2010
    Research Assistant at the Department of Nuclear Medicine of UKM, Germany

  • 2013
    Karl-Oberdisse prize of the North Rhine-Westphalian Society for Endocrinology and Diabetology, Germany

  • 2016
    Alavi–Mandell Award for Articles Published in 2015 (Differentiated Thyroid Cancer Patients More Than 60 Years Old Paradoxically Show an Increased Life Expectancy)

  • 2018
    Prize for the best scientific work of the Limassol Medical Association

  • 2020
    Gold Award in Innovation (Healthcare Business Awards)

  1. Giovanella L, Milan L, Roll W, Weber M, Schenke S, Kreissl M, Vrachimis A, Pabst K, Murat T, Petranović Ovčariček P, Campenni A, Görges R, Ceriani L. Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer: a decision tree analysis in a European multicenter series. Clin Chem Lab Med. 2024 May 7. doi: 10.1515/cclm-2024-0405. Online ahead of print.
  2. Kreissl MC, Ovčariček PP, Campenni A, Vrachimis A, Tuncel M, Giovanella L. The European Association of Nuclear Medicine (EANM)'s Response to the 2023 European Thyroid Association (ETA) clinical practice guidelines for thyroid nodule management and nuclear medicine: a deliberate oversight? Eur J Nucl Med Mol Imaging. 2024;51:1678-1681. doi: 10.1007/s00259-023-06571-z.
  3. Adebahr S, Althaus A, Scharl S, Strouthos I, Farolfi A, Serani F, Lanzafame H, Trapp C, Koerber SA, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Grosu AL, Kroeze SGC, Guckenberger M, Fanti S, Hruby G, Emmett L, Belka C, Schmidt-Hegemann NS, Henkenberens C, Aebersold DM, Wiegel T, Afshar-Oromieh A, Zamboglou C, Shelan M. The prognostic significance of a negative PSMA-PET scan prior to salvage radiotherapy following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51: 558-567. doi: 10.1007/s00259-023-06438-3.
  4. Holzschuh JC, Mix M, Ruf J, Hölscher T, Kotzerke J, Vrachimis A, Doolan P, Ilhan H, Marinescu IM, Spohn SKB, Fechter T, Kuhn D, Bronsert P, Gratzke C, Grosu R, Kamran SC, Heidari P, Ng TSC, Könik A, Grosu AL, Zamboglou C. Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer. Radiother Oncol. 2023; 188:109774. doi: 10.1016/j.radonc.2023.109774.
  5. Petranović Ovčariček P, Campenni A, de Keizer B, Deandreis D, Kreissl MC, Vrachimis A, Tuncel M, Giovanella L. Molecular Theranostics in Radioiodine-Refractory Differentiated Thyroid Cancer. Cancers (Basel). 2023 Aug 27;15(17):4290. doi: 10.3390/cancers15174290.
  6. Scharl S, Zamboglou C, Strouthos I, Farolfi A, Serani F, Lanzafame H, Giuseppe Morganti A, Trapp C, Koerber SA, Debus J, Peeken JC, Vogel MME, Vrachimis A, Spohn SKB, Ruf J, Grosu AL, Ceci F, Fendler WP, Bartenstein P, Kroeze SGC, Guckenberger M, Krafcsik M, Klopscheck C, Fanti S, Hruby G, Emmett L, Belka C, Stief C, Schmidt-Hegemann NS, Henkenberens C, Mayer B, Miksch J, Shelan M, Aebersold DM, Thamm R, Wiegel T. Salvage radiotherapy is effective in patients with PSMA-PET-negative biochemical recurrence- results of a retrospective study. Radiother Oncol. 2023;184:109678. doi:10.1016/j.radonc.2023.109678.
  7. Giovanella L, Milan L, Roll W, Weber M, Schenke S, Kreissl M, Vrachimis A, Pabst K, Murat T, Petranovic Ovcaricek P, Riemann B, Ceriani L, Campenni A, Görges R. Postoperative thyroglobulin as a yard-stick for radioiodine therapy: decision tree analysis in a European multicenter series of 1317 patients with differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2023;50:2767-2774. doi: 10.1007/s00259-023-06239-8.
  8. Solomonidou N, Germanou D, Strouthos I, Karagiannis E, Farolfi A, Koerber SA, Debus J, Peeken JC, Vogel ME, Vrachimis A, Spohn SKB, Shelan M, Aebersold D, Grosu AL, Ceci F, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Hruby G, Scharl S, Wiegel T, Bartenstein P, Henkenberens C, Emmett L, Schmidt-Hegemann NS, Ferentinos K, Zamboglou C. PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml. Eur J Nucl Med Mol Imaging. 2023;50:2529-2536. doi: 10.1007/s00259-023-06185-5
  9. Zamboglou C, Peeken JC, Janbain A, Katsahian S, Strouthos I, Ferentinos K, Farolfi A, Koerber SA, Deb us J, Vogel ME, Combs SE, Vrachimis A, Morganti AG, Spohn SKB, Shelan M, Aebersold DM, Grosu AL, Ceci F, Henkenberens C, Kroeze SGC, Guckenberger M, Fanti S, Belka C, Bartenstein P, Hruby G, Scharl S, Wiegel T, Emmett L, Arnoux A, Schmidt-Hegemann NS. Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer. JAMA Netw Open. 2023;6:e2314748. doi: 10.1001/jamanetworkopen.2023.
  10. Petranović Ovčariček P, Giovanella L, Vrachimis A. Parathyroid imaging. Q J Nucl Med Mol Imaging. 2023 Jun;67:93-95. doi: 10.23736/S1824-4785.23.03511-2. Epub 2023 Feb 7.
  11. Luisa Garo M, Deandreis D, Campennì A, Vrachimis A, Petranovic Ovcaricek P, Giovanella L. Accuracy of papillary thyroid cancer prognostic nomograms: a systematic review. Endocr Connect. 2023 Mar 10;12:e220457. doi: 10.1530/EC-22-0457.
  12. Petranović Ovčariček P, Kreissl MC, Campenni A, de Keizer B, Tuncel M, Vrachimis A, Deandreis D, Giovanella L. SNMMI/EANM practice guideline vs. ETA Consensus Statement: differences and similarities in approaching differentiated thyroid cancer management-the EANM perspective. Eur J Nucl Med Mol Imaging. 2022 Oct;49:3959-3963. doi: 10.1007/s00259-022-05935-1.
  13. Zamboglou C, Strouthos I, Sahlmann J, Farolfi A, Serani F, Medici F, Cavallini L, Morganti AG, Trapp C, Koerber SA, Peeken JC, Vogel MME, Schiller K, Combs SE, Eiber M, Vrachimis A, Ferentinos K, Spohn SKB, Kirste S, Gratzke C, Ruf J, Grosu AL, Ceci F, Fendler WP, Miksch J, Kroeze S, Guckenberger M, Lanzafame H, Fanti S, Hruby G, Wiegel T, Emmett L, Schmidt-Hegemann NS, Henkenberens C. Metastasis-Free Survival and Patterns of Distant Metastatic Disease After Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET)-Guided Salvage Radiation Therapy in Recurrent or Persistent Prostate Cancer After Prostatectomy. Int J Radiat Oncol Biol Phys. 2022 Aug 1;113:1015-1024. doi: 10.1016/j.ijrobp.2022.04.048.
  14. Avram AM, Giovanella L, Greenspan B, Lawson SA, Luster M, Van Nostrand D, Peacock JG, Ovčariček PP, Silberstein E, Tulchinsky M, Verburg FA, Vrachimis A. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J Nucl Med. 2022 Jun;63(6):15N-35N.
  15. Tuncel M, Vrachimis A, Campenni A, de Keizer B, Verburg FA, Kreissl MC, Ovcaricek PP, Geliashvili T, Giovanella L. To give or not to give? A critical appraisal of a clinical trial on radioiodine treatment. Eur J Nucl Med Mol Imaging. 2022 May 18. doi: 10.1007/s00259-022-05841-6
  16. Vrachimis A. Editorial: Principles and Clinical Applications of Interstitial Brachytherapy. Front Oncol. 2022 Mar 9;12:877165. doi: 10.3389/fonc.2022.877165. eCollection 2022.
  17. Giovanella L, Deandreis D, Vrachimis A, Campenni A, Petranovic Ovcaricek P. Molecular Imaging and Theragnostics of Thyroid Cancers. Cancers (Basel). 2022 Mar 1;14(5):1272. doi: 10.3390/cancers14051272.
  18. Tsechelidis I, Vrachimis A. PSMA PET in Imaging Prostate Cancer. Front Oncol. 2022 Jan 28;12:831429. doi: 10.3389/fonc.2022.831429. eCollection 2022.
  19. Giannoula E, Iakovou I, Giovanella L, Vrachimis A. Updated clinical management guidance during the COVID-19 pandemic: thyroid nodules and cancer. Eur J Endocrinol. 2022 Feb 28;186(4):G1-G7. doi: 10.1530/EJE-21-0716.
  20. Huettmann C, Stelljes M, Sivalingam S, Fobker M, Vrachimis A, Exler A, Wenning C, Wempe C, Penke M, Buness A, Ludwig KU, Muckenthaler MU, Steinbicker AU. Iron Deficiency Caused by Intestinal Iron Loss-Novel Candidate Genes for Severe Anemia. Genes (Basel). 2021 Nov 24;12(12):1869. doi: 10.3390/genes12121869.
  21. Forrer F, Fischer GF, Maas O, Giovanella L, Hoffmann M, Iakovou I, Luster M, Mihailovic J, Petranovic Ovčariček P, Vrachimis A, Zerdoud S, Putora PM. Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy. Oncology. 2022;100(2):74-81. doi: 10.1159/000520938.
  22. Fesas A, Giannoula E, Vrachimis A, Doumas A, Wenning C, Didagelos M, Iakovou I. Cardiac Autonomic Nervous System and Ventricular Arrhythmias: The Role of Radionuclide Molecular Imaging. Diagnostics (Basel). 2021 Jul 15;11(7):1273. doi: 10.3390/diagnostics11071273.
  23. Ferentinos K, Karagiannis E, Strouthos I, Vrachimis A, Doolan PJ, Zamboglou N. Computed tomography guided interstitial percutaneous high-dose-rate brachytherapy in the management of lung malignancies. A review of the literature. Brachytherapy. 2021 Jul-Aug;20(4):892-899. doi: 10.1016/j.brachy.2021.03.012.
  24. Campennì A, Vrachimis A, Siracusa M, Baldari S, Giovanella L. Usefulness of 123I-spect/ct to assess the response to initial therapy in differentiated thyroid cancer patients. Endocrine. 2021 Oct;74(1):193-196. doi: 10.1007/s12020-021-02737-7.
  25. Vrachimis A, Ferentinos K, Demetriou E, Ioannides C, Zamboglou N. PET/CT imaging of prostate cancer in the era of small molecule prostate specific membrane antigen targeted tracers. Hell J Nucl Med. 2020 Sep-Dec;23(3):339-345. doi: 10.1967/s002449912211.
  26. Petranović Ovčariček P, Verburg FA, Hoffmann M, Iakovou I, Mihailovic J, Vrachimis A, Luster M, Giovanella L. Higher thyroid hormone levels and cancer. Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):808-821. doi: 10.1007/s00259-020-05018-z.
  27. Giannoula E, Vrachimis A, Giovanella L, Chatzipavlidou V, Iakovou I. Nuclear thyroidology in pandemic times: The paradigm shift of COVID-19. Hell J Nucl Med. 2020 May-Aug;23 Suppl:41-50.
  28. Reiners C, Schneider R, Platonova T, Fridman M, Malzahn U, Mäder U, Vrachimis A, Bogdanova T, Krajewska J, Elisei R, Vaisman F, Mihailovic J, Costa G, Drozd V. Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey. Front Endocrinol (Lausanne). 2020 Jul 10;11:381. doi: 10.3389/fendo.2020.00381.
  29. Schleupner MC, Riemann B, Schäfers M, Backhaus P, Vrachimis A. Impact of FDG-PET on therapy management and outcome of differentiated thyroid carcinoma patients with elevated thyroglobulin despite negative iodine scintigraphy. Nuklearmedizin. 2020 Sep;59(5):356-364.
  30. Vrachimis A, Iakovou I, Giannoula E, Giovanella L. ENDOCRINOLOGY IN THE TIME OF COVID-19: Management of thyroid nodules and cancer. Eur J Endocrinol. 2020 Jul;183(1):G41-G48. doi: 10.1530/EJE-20-0269.
  31. Verburg FA, Giovanella L, Hoffmann M, Iakovou I, Mihailovic J, Ovcaricek PP, Vrachimis A, Luster M. New! F-18-based PET/CT for sodium-iodine-symporter- targeted imaging! Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2484-2486.
  32. Giovanella L, Verburg FA, Ovčariček PP, Iakovou I, Mihailovic J, Vrachimis A, Zerdoud S, Hoffmann M, Luster M. "Quid autem vides festucam in oculo fratris tui et trabem in oculo tuo non vide" on the hyperthyroidism-induced mortality and antithyroid drug-induced side effects in the era of radioiodine fake news. Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1342-1344.
  33. Wenning C, Vrachimis A, Pavenstädt HJ, Reuter S, Schäfers M. Coronary artery calcium burden, carotid atherosclerotic plaque burden, and myocardial blood flow in patients with end-stage renal disease: A non-invasive imaging study combining PET/CT and 3D ultrasound. J Nucl Cardiol. 2020 Mar 5. doi: 10.1007/s12350-020-02080-w.
  34. Verburg FA, Hoffmann M, Iakovou I, Konijnenberg MK, Mihailovic J, Gabina PM, Petranović Ovčariček P, Reiners C, Vrachimis A, Zerdoud S, Giovanella L, Luster M. Errare humanum est, sed in errare perseverare diabolicum: methodological errors in the assessment of the relationship between I-131 therapy and possible increases in the incidence of malignancies. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-019-04580-5
  35. Roll W, Riemann B, Schäfers M, Stegger L, Vrachimis A. 177Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer: A Single Center Experience. Clin Nucl Med. 2018;43:e346-e351.
  36. Krämer J, Lueg G, Schiffler P, Vrachimis A, Weckesser M, Wenning C, Pawlowski M, Johnen A, Teuber A, Wersching H, Meuth SG, Duning T. Diagnostic Value of Diffusion Tensor Imaging and Positron Emission Tomography in Early Stages of Frontotemporal Dementia. J Alzheimers Dis. 2018;63:239-253.
  37. Zumhagen S, Vrachimis A*, Stegger L, Kies P, Wenning C, Ernsting M, Müller J, Seebohm G, Paul M, Schäfers K, Stallmeyer B, Schäfers M, Schulze-Bahr Impact of presynaptic sympathetic imbalance in long-QT syndrome by positron emission tomography. Heart. 2018;104:332-339
  38. Avramovic N, Dell'Aquila AM, Weckesser M, Milankovic D, Vrachimis A, Sindermann JR, Wenning C.Metabolic volume performs better than SUVmax in the detection of left ventricular assist device driveline infection. Eur J Nucl Med Mol Imaging. 2017;44:1870-1877.
  39. Gonzalez Carvalho JM, Görlich D, Schober O, Wenning C, Riemann B, Verburg FA, Vrachimis A. Evaluation of 131I scintigraphy and stimulated thyroglobulin levels in the follow up of patients with DTC: a retrospective analysis of 1420 patients. Eur J Nucl Med Mol Imaging. 2017;44: 744- 756.
  40. Noto B, Vrachimis A, Schäfers M, Stegger L, Rahbar K. Subacute Stroke Mimicking Cerebral Metastasis in 68Ga-PSMA-HBED-CC PET/CT. Clin Nucl 2016;41:e449-51.
  41. Vrachimis A, Stegger L, Wenning C, Noto B, Burg MC, Konnert JR, Allkemper T, Heindel W, Riemann B, Schäfers M, Weckesser M. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine- refractory differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2016;43:1765-72.
  42. Fricke IB, Viel T, Worlitzer MM, Collmann FM, Vrachimis A, Faust A, Wachsmuth L, Faber C, Dollé F, Kuhlmann MT, Schäfers K, Hermann S, Schwamborn JC, Jacobs AH. 6- hydroxydopamine-induced Parkinson's disease- like degeneration generates acute microgliosis and astrogliosis in the nigrostriatal system but no bioluminescence imaging-detectable alteration in adult neurogenesis. Eur J Neurosci. 2016;43:1352-65.
  43. Büther F, Vrachimis A, Becker A, Stegger L. Impact of MR-safe headphones on PET attenuation in combined PET/MRI scans. EJNMMI Res. 2016;6(1):20.
  44. Vrachimis A, Weckesser M, Schäfers M, Stegger L. Imaging of differentiated thyroid carcinoma: (124)I-PET/MRI may not be superior to (124)I-PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:1183-4.
  45. Vrachimis A, Riemann B, Mäder U, Reiners C, Verburg FA. Endogenous TSH levels at I-131 ablation do not influence ablation success, recurrence free survival or differentiated thyroid cancer related mortality. Eur J Nucl Med Mol Imaging. 2016;43:224–231.
  46. Wenning C, Vrachimis A, Penning A, Stypmann J, Schäfers Inhomogeneous myocardial perfusion in gated SPECT is associated with the development of systolic allograft dysfunction in heart transplant recipients. EJNMMI Res. 2015;5:51.
  47. Vrachimis A, Burg MC, Wenning C, Allkemper A, Weckesser M, Schäfers M, Stegger L. [18F]FDG-PET/CT outperforms [18F]FDG-PET/MRI in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. Eur J Nucl Med Mol Imaging. 2016;43:212-20.
  48. Vrachimis A, Honold L, Faust A, Hermann S, Schäfers M. New molecular probes of vascular inflammation. Q J Nucl Med Mol Imaging. 2016;60:194-204.
  49. Zinnhardt B, Viel T, Wachsmuth L, Vrachimis A, Wagner S, Breyholz HJ, Faust A, Hermann S, Kopka K, Faber C, Dollé F, Pappata S, Planas AM, Tavitian B, Schäfers M, Sorokin LM, Kuhlmann MT, Jacobs Multimodal imaging reveals temporal and spatial microglia and matrix metalloproteinase activity after experimental stroke. J Cereb Blood Flow Metab. 2015;35:1711-21
  50. Vrachimis A, Wenning C, Gerß J, Dralle H, Tabassi MV, Schober O, Riemann B. Not all DTC patients with N positive disease deserve the attribution “high risk”. Contribution of the MSDS trial. JSO 2015;112:9-14.
  51. Maier TM, Schober O, Gerß J, Görlich D, Wenning C, Riemann R, Vrachimis A. Differentiated thyroid cancer patients > 60 years of age paradoxically show an increased life expectancy. JNM 2015;56:190-5.
  52. Reuter S, Vrachimis A, Huss S, Wardelmann E, Weckesser M, Pavenstädt H. A Challenging Case of Rapid Progressive Kaposi Sarcoma After Renal Transplantation: Diagnostics by FDG PET/CT. Medicine (Baltimore). 2014;93:e67.
  53. Vrachimis A, Gerss J, Stoyke M, Wittekind C, Maier T, Wenning C, Rahbar K, Schober O, Riemann B. No Significant Difference in the Prognostic Value of the 5(th) and 7(th) Editions of AJCC Staging for Differentiated Thyroid Cancer. Clin Endocrinol (Oxf). 2014;80:911-7.
  54. Vrachimis A, Schäfers M, Weckesser M. Positronenemissions-tomographische Diagnostik kindlicher Sarkome. Der Nuklearmediziner 2014;37:242-249.
  55. Wenning C, Lange PS, Schülke C, Vrachimis A, Mönnig G, Schober O, Eckardt L, Schäfers M. Pulmonary vein isolation in patients with paroxysmal atrial fibrillation is associated with regional cardiac sympathetic denervation. EJNMMI Res. 2013;3:81.
  56. Vrachimis A, Kurt Werner S, Jürgens H, Schober O, Weckesser M, Riemann B. Cerebral metastases from thyroid carcinoma: complete remission following radioiodine treatment. Dtsch Arztebl Int. 2013;110:861-6.
  57. Wenning C, Rahbar K, Vrachimis A, Schober O, Schäfers M, Stegger L. Myocardial perfusion imaging and coronary calcium scoring with a two-slice SPECT/CT system: can the attenuation map be calculated from the calcium scoring CT scan? Eur J Nucl Med Mol Imaging. 2013;40:1069-76.
  58. Vrachimis A, Riemann B, Gerss J, Maier T, Schober O. Peace of mind for patients with differentiated thyroid cancer? Nuklearmedizin. 2013;52:115-20.
  59. Rahbar K, Colombo-Benkmann M, Haane C, Wenning C, Vrachimis A, Weckesser M, Schober Intraoperative 3-D mapping of parathyroid adenoma using freehand SPECT. EJNMMI Res. 2012;2:51.
  60. Vrachimis A, Hermann S, Máthé D, Schober O, Schäfers M. Systematic evaluation of 99mTc-tetrofosmin versus 99mTc-sestamibi to study murine myocardial perfusion in small animal SPECT/CT. EJNMMI Res. 2012;2:21.
  61. Vrachimis A, Schober O, Riemann B. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. Nuklearmedizin. 2012;51:67- 72.
  62. Vrachimis A, Dirksen U, Wessling J, Wenning C, Stegger L, Franzius C, Juergens H, Schober O, Weckesser M. PET surveillance of patients with Ewing sarcomas of the trunk: Must the lower legs be included? Nuklearmedizin. 2010;49:183-6.
  1. Vrachimis A, Schäfers M, Stegger L, Wenning C. Autonomic Imaging in Ventricular Arrhythmias in Autonomic Innervation of the Heart Role of Molecular Imaging. Slart RHJA, Tio RA, Elsinga PH, Schwaiger M. (Eds.) 2015, Springer. ISBN 978-3-662-45073-4

  2. Vrachimis A, Schober O, Riemann B. Radiojodtherapie bei differenziertem Schilddrüsenkarzinom: Schilddrüsenhormon-Entzug, rhTSH oder Kombination von beiden? in SCHILDDRÜSE Grußendorf M (Ed.) 2012 Lehmanns Auflage. ISBN 978-3865414755

  3. Vrachimis A, Franzius C, Schober O. Therapie der Hyperthyreose aus Sicht der Nuklearmedizin in Endokrine Chirurgie. Colombo- Benkmann M, Senninger N. (Eds) 2007, tdv. Verlag, ISBN 978-3-939838-22-7.
German Medical Institute
Copyrights © 2024 | All Rights Reserved
Facebook Instagram Linkedin Bullhorn

Centers

German Oncology Center
Diagnostic Center
Surgery Center
Cardiovascular Center
...view all centers

Departments

Radiation Oncology
Haematology and Transplantation
Medical Oncology
Cardiac Surgery
...view all departments

Company

About Us
Job Vacancies
Contact Us

Certificates

The portal

Ι am a patient, a relative

I am a healthcare provider

I am a student, a researcher

About Us

Our Philosophy

Our Board of Directors

Administration

Patients Portal

International Patients

Donations

Contact us

24-hour Emergency Helpline

(+357) 25 208 000

Emergencies are not yet accredited of the General Health Care System

(+357) 25 208 000

Emergencies are not yet accredited of the General Health Care System.

close menu icon

Donate

Dr. Aris Angouridis

internist
About me:

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Email: [email protected]
Phone: (+357) 25 208 000